Undiagnosed pre-diabetes highly prevalent in early Alzheimer's disease study

When Georgetown University neurologist R. Scott Turner, MD, PhD, began enrolling people with mild to moderate Alzheimer's disease into a nationwide study last year, he expected to find only a handful of participants with undiagnosed glucose intolerance, as all the patients were already under a doctor's care and those with known diabetes were excluded. But Turner says he was "shocked" by how many study participants were found to have pre-diabetes—a finding that is triggering important questions.

Turner's study examines resveratrol, a compound found in red grapes and red wine, to see if it might change in patients with mild to moderate Alzheimer's disease (AD). Turner says resveratrol is thought to act on proteins in the brain in a way that mimics effects of a low-calorie diet.

"We know from animal studies that prevents diseases of aging such as diabetes and Alzheimer's," explains Turner, director of the Georgetown University Medical Center's Memory Disorders Program. "On the flip side of the coin, having diabetes increases one's risk of developing AD. So perhaps by improving glucose tolerance, we will prevent or delay both diabetes and Alzheimer's."

To join the resveratrol study, participants were first given a tolerance test to obtain a baseline level, and then retested two hours after eating. During digestion, the increases, but the pancreas produces insulin to lower it. A high sugar level after two hours reveals (pre-diabetes) or diabetes if the level is very high.

"The number of people with glucose intolerance (pre-diabetes) was much higher than expected," says Turner. "I was surprised by how many people didn't know they were pre-diabetic, and these are individuals who already get the best medical care."

Five (4 percent) of 128 participants had impaired fasting glucose levels while three others (2 percent) had findings consistent with . Of the 125 subjects who completed the two-hour test, 38 (30 percent) demonstrated glucose intolerance while 16 (13 percent) had results consistent with diabetes. Thus, the overall prevalence of impaired glucose tolerance or diabetes at two hours was 43 percent – or almost half of the individuals recruited to the study.

Turner asks, "How does glucose intolerance or diabetes lead to AD? Does the inflammation associated with AD trigger glucose intolerance? Or do both events create a vicious cycle of Alzheimer's and glucose intolerance?"

Turner's study isn't designed to answer these questions, but it might provide important clues. Turner says while a glucose tolerance test is not typically ordered by neurologists, "this result suggests that perhaps we should test all our patients with early Alzheimer's. It's a simple, inexpensive study that reveals critical health information."

Turner will discuss his findings at the Alzheimer's Association International Congress in Boston on July 14.

The resveratrol study is sponsored by the Alzheimer's Disease Cooperative Study through a grant from the National Institute on Aging. Turner reports no personal financial interests related to the study.

add to favorites email to friend print save as pdf

Related Stories

Study suggests gut metagenome link to Type 2 diabetes

May 30, 2013

(Medical Xpress)—A team made up of researchers from Sweden and Denmark has found evidence of a possible link between gut metagenome and Type 2 diabetes. In their paper published in the journal Nature, the te ...

Recommended for you

Putting dementia carers in control

23 hours ago

Experts will explore how improved support and powers for people caring for loved-ones with dementia can improve quality of life for both patients and carers around the UK.

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

jamesinraro
not rated yet Jul 15, 2013
The ability of bioforte resveratrol, the supplement form used in most clinical trials. to lower glucose and improve insulin sensitivity, a benefit to Type 2 Diabetics and other conditions, was confirmed in two clinical trials done at Albert Einstein Med College three years ago, and further confirmed by a human trial using transmax resveratrol done by two pharmaceutical colleges on patients using Metformin.